Danazol for Children With Immune Thrombocytopenic Purpura

Weinblatt, Mark E.; Kochen, Joseph; Ortega, Jorge A.

doi:10.1001/archpedi.1988.02150120071043

Cited by 17 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limited experience with pediatric use has been obtained in patients treated for idiopathic thrombocytopenic purpura. 62 Treatment with the lowest effective maintenance dose of danazol (2.5 mg/kg per day; 50 mg/day starting dose; if necessary, up to a maximum of 200 mg/day) and intermittent dosage regimens (ie, doses repeated every other day or at 3-day intervals) do not interfere with growth and mental development and may prevent potential adverse effects such as hirsuitism, virilization, weight gain, myalgia, headache, libido changes, elevation of serum transaminase levels, microhematuria, menstruation irregularities, and lipidprofile changes. 21,52,58,60,63 In recent years, several case reports have been published on the efficacy and favorable safety profile of oxandrolone in pediatric patients.…”

Section: Long-term Prophylaxismentioning

confidence: 99%

Management of Hereditary Angioedema in Pediatric Patients

et al. 2007

View full text Add to dashboard Cite

Hereditary angioneurotic edema is a rare disorder caused by the congenital deficiency of C1 inhibitor. Recurring angioedematous paroxysms that most commonly involve the subcutis (eg, extremities, face, trunk, and genitals) or the submucosa (eg, intestines and larynx) are the hallmarks of hereditary angioneurotic edema. Edema formation is related to reduction or dysfunction of C1 inhibitor, and conventional therapy with antihistamines and corticosteroids is ineffective. Manifestations occur during the initial 2 decades of life, but even today there is a long delay between the onset of initial symptoms and the diagnosis of hereditary angioneurotic edema. Although a variety of reviews have been published during the last 3 decades on the general management of hereditary angioneurotic edema, little has been published regarding management of pediatric hereditary angioneurotic edema. Thus, we review our experience and published data to provide an approach to hereditary angioneurotic edema in childhood.

show abstract

Section: Long-term Prophylaxismentioning

confidence: 99%

Management of Hereditary Angioedema in Pediatric Patients

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Acceleration of bone age makes the use of danazol problematic in prepubertal children. 10 None of the patients in this study received rituximab.…”

Section: Introductionmentioning

confidence: 96%

“…5,6 Many clinicians would use a series of other treatments including danazol, azathioprine, plasmapheresis, vincristine, cyclophosphamide, platelet transfusion, and especially splenectomy. [7][8][9][10] The latter is often but not always effective. 11 However, the long-term complications of splenectomy, in addition to sepsis, are not well-defined.…”

Section: Introductionmentioning

confidence: 99%

“…Danazol and azathioprine were chosen because the efficacy of each had been well described in relatively large numbers of patients and also because of their tolerability and low, generally nonoverlapping toxicity profiles. [8][9][10] Danazol also suppresses menses, providing additional benefit to women who may have had clinically significant menometrorrhagia. Hirsutism with this agent is less of a problem than development of acne.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP)

Boruchov

Gururangan

Driscoll

et al. 2007

Blood

View full text Add to dashboard Cite

“…[4][5][6][7][8][9] Two previous reports of ascorbic acid trials in adults have been described in the medical literature. 'O,&dquo; In this report, we describe our experience with ascorbic acid in a group of seven children with chronic ITP.…”

mentioning

confidence: 99%